ERBB2 and cancer: In response to anti-EGFR therapy resistance, HER2 (Human Epidermal Growth Factor Receptor) therapy was developed (amplified and/or overexpressed ERBB2/HER2 triggered constant signals for cell division and survival, driving cancer progression) [8].